A Phase 1/2 Study of CC-122 in Combination With R-CHOP for Previously Untreated Poor-Risk (IPI ≥3) Diffuse Large B-Cell Lymphoma and Transformed Lymphomas

Trial Profile

A Phase 1/2 Study of CC-122 in Combination With R-CHOP for Previously Untreated Poor-Risk (IPI ≥3) Diffuse Large B-Cell Lymphoma and Transformed Lymphomas

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Mar 2018

At a glance

  • Drugs Avadomide (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine
  • Indications Diffuse large B cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 29 Nov 2017 Planned primary completion date changed from 29 Oct 2020 to 28 Feb 2020.
    • 29 Nov 2017 Status changed from not yet recruiting to recruiting.
    • 18 Aug 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top